Skip to main content
letter
. 2021 Jan 15;203(2):245–249. doi: 10.1164/rccm.202007-2638LE

Table 2.

Association with Mortality of Clinical Characteristics, Comorbidities, Lung Function, and Treatment by Cox Regression Analysis

  Univariable Analysis
Multivariable Analysis
  HR (95% CI) P Value HR (95% CI) P Value
Sex, M/F 4.22 (1.47–12.06) 0.01 3.90 (1.17–13.04) 0.03
Age, yr 1.07 (1.03–1.10) <0.01 1.07 (1.04–1.11) <0.01
Body mass index, kg ⋅ m−2 1.02 (0.96–1.09) 0.51
Underlying ILD, fibrotic/other 2.15 (1.06–4.35) 0.04
Comorbidities, yes/no        
 Obesity 1.01 (0.41–2.47) 0.99
 Hypertension 2.48 (1.18–5.21) 0.02
 Cardiovascular disease 3.20 (1.55–6.59) <0.01
 Diabetes mellitus 1.46 (0.69–3.06) 0.32
 Chronic kidney disease 1.81 (0.63–5.20) 0.27
 Cancer or hemopathy 3.21 (1.12–9.21) 0.03 5.82 (1.88–18.08) <0.01
 Pulmonary hypertension 2.88 (1.22–6.83) 0.02
Pulmonary characteristics        
 FVC% predicted 0.98 (0.96–0.99) 0.02
 Corrected DlCO% predicted 0.96 (0.94–0.99) <0.01
 Oxygen supplementation at home 4.25 (2.02–8.91) <0.01 4.56 (2.13–9.78) <0.01
Treatment at baseline, yes/no        
 Antifibrotic medication 3.09 (1.27–7.55) 0.01
 Glucocorticoids 1.06 (0.51–2.18) 0.88
 Immunosuppressive drugs 0.58 (0.26–1.30) 0.19
COVID-19–related medications, yes/no        
 Any 1.43 (0.70–2.92) 0.32
 Lopinavir/ritonavir 1.61 (0.49–5.30) 0.43
 Azithromycine 0.23 (0.03–1.72) 0.15
 Hydroxychloroquine 1.58 (0.60–4.11) 0.35
 Glucocorticoids 1.15 (0.40–3.28) 0.80

Definition of abbreviations: CI = confidence interval; COVID-19 = coronavirus disease; HR = hazard ratio; ILD = interstitial lung disease. Bold indicates P < 0.05.